Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: An evaluation of different methods

Journal of Immunotherapy

Volumn 33, Issue 2, 2010, Pages 185-199

  Kremser, Andreas ^a   Dreyig, Julia ^a   Grabrucker, Christine ^a   Liepert, Anja ^a   Kroell, Tanja ^a   Scholl, Nina ^a   Schmid, Christoph ^b   Tischer, Johanna ^a   Kufner, Stefanie ^a   Salih, Helmut ^c   Kolb, Hans Jochem ^a,d   Schmetzer, Helga ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Municipal Hospital   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Acute myeloid leukaemia; Dendritic cells; Immunotherapy; Myelodysplastic syndromes; Serum free culture

Indexed keywords

CALCIUM IONOPHORE; CYTOKINE; PICIBANIL; POLYINOSINIC POLYCYTIDYLIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; CELL DIFFERENTIATION; CELL MATURATION; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MIXED LYMPHOCYTE CULTURE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGEN PRESENTATION; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL SEPARATION; CULTURE MEDIA, SERUM-FREE; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PICIBANIL; POLY I-C; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77649163905     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181b8f4ce     Document Type: Article

References (53)

1. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin Proc. 2006;81:247-260.
2. Woiciechowsky A, Regn S, Kolb HJ, et al. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia. 2001;15:246-255.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
4. Costello RT, Rey J, Fauriat C, et al. New approaches in the immunotherapy of haematological malignancies. Eur J Hae-matol. 2003;70:333-345.
5. Sallusto F, Lanzavecchia A. The instructive role of dendritic cells on T-cell responses. Arthritis Res. 2002;4(suppl 3): S127-S132.
6. Lee AW, Truong T, Bickham K, et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine. 2002;20(suppl 4):A8-A22.
7. Westers TM, Stam AG, Scheper RJ, et al. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia. Cancer Immunol Immunother. 2003;52:17-27.
8. Houtenbos I, Westers TM, Stam AG, et al. Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation. Cancer Immunol Immunother. 2003;52:455-462.
9. Rouas R, Lewalle P, El Ouriaghli F, et al. Poly (I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive IL-12. Int Immunol. 2004;16: 767-773.
10. Sato M, Takayama T, Tanaka H, et al. Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK-432 combined with prostaglandin E (2). Cancer Sci. 2003;94:1091-1098.
11. Kufner S, Fleischer RP, Kroell T, et al. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. Cancer Immunol Immunother. 2005;54:953-970.
12. Mackensen A, Drager R, Schlesier M, et al. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human pep-tide-pulsed dendritic cells. Cancer Immunol Immunother. 2000; 49:152-156.
13. Roddie PH, Horton Y, Turner ML. Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1. Leukemia. 2002;16:84-93.
14. Schmetzer HM, Kremser A, Loibl J, et al. Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo. Leukemia. 2007;21: 1338-1341.
15. Bennett JM, Komrokji RS. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology. 2005;10(suppl 1):258-269.
16. Hayhoe FG. Classification of acute leukaemias. Blood Rev. 1988;2:186-193.
17. Schoch C, Haferlach T. Cytogenetics in acute myeloid leukemia. Curr Oncol Rep. 2002;4:390-397.
18. Philpott NJ, Turner AJ, Scopes J, et al. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood. 1996;87:2244-2251.
19. Bender A, Sapp M, Schuler G, et al. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods. 1996;196:121-135. (Pubitemid 26306734)
20. Sanchez-Sanchez N, Riol-Blanco L, Rodriguez-Fernandez JL. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J Immunol. 2006;176:5153-5159.
21. Kienzle N, Olver S, Buttigieg K, et al. The fluorolysis assay, a highly sensitive method for measuring the cytolytic activity of T cells at very low numbers. J Immunol Methods. 2002;267: 99-108.
22. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894-1907.
23. Smith M, Barnett M, Bassan R, et al. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol. 2004;50:197-222.
24. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med. 2005;56:1-16
25. Balaian L, Ball ED. Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies. Leuk Res. 2004;28:821-829
26. Balaian L, Ball ED. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia. 2006;20: 2093-2101.
27. Oka Y, Tsuboi A, Elisseeva OA, et al. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers. Scientific World Journal. 2007;7:649-665.
28. Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother. 2003;52:328-337.
29. Brouwer RE, Hoefnagel J, Borger van Der BB et al. Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. Br J Haematol. 2001;115:298-308.
30. Konopleva M, Konoplev S, Hu W, et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002;16:1713-1724.
31. Vollmer M, Li L, Schmitt A, et al. Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia. Br J Haematol. 2003; 120:1000-1008.
32. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
33. Kolb HJ, Schmid C, Chen X, et al. Adoptive immunotherapy in chimeras with donor lymphocytes. Acta Haematol. 2003;110: 110-120.
34. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108: 1092-1099.
35. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.
36. Choudhury BA, Liang JC, Thomas EK, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 1999;93:780-786.
37. Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117: 1195-1203.
38. Hsu AK, Kerr BM, Jones KL, et al. RNA loading of leukemic antigens into cord blood-derived dendritic cells for immuno-therapy. Biol Blood Marrow Transplant. 2006;12:855-867.
39. Kufner S, Zitzelsberger H, Kroell T, et al. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions. Scand J Immunol. 2005;62:86-98. (Pubitemid 41029503)
40. Engels FH, Kreisel D, Faries MB, et al. Calcium ionophore activation of chronic myelogenous leukemia progenitor cells into dendritic cells is mediated by calcineurin phosphatase. Leuk Res. 2000;24:795-804.
41. Loseke S, Grage-Griebenow E, Heine H, et al. In vitro-generated viral double-stranded RNA in contrast to polyinosinic:polycy-tidylic acid induces interferon-alpha in human plasmacytoid dendritic cells. Scand J Immunol. 2006;63:264-274.
42. Li L, Reinhardt P, Schmitt A, et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol Immunother. 2005;54:685-693.
43. Roddie H, Klammer M, Thomas C, et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the im-munotherapy of acute myeloid leukaemia. Br J Haematol. 2006;133:152-157.
44. Brouwer RE, van der HM, Kluin-Nelemans HC, et al. The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses. Hum Immunol. 2000;61:565-574.
45. Graf M, Reif S, Hecht K, et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol. 2005;84:287-297.
46. DreyXig J, Kremser A, Schmid C, et al. Surface marker expression profiles of dendritic cells (DC) from blasts in AML and MDS to characterize and quantity DC in experimental settings. submitted for publication. 2009.
47. Houtenbos I, Westers TM, Hess CJ, et al. Flt-3 internal tandem duplication hampers differentiation of AML blasts towards leukemic dendritic cells. Leukemia. 2006;20: 1892-1895.
48. Westers TM, Houtenbos I, Snoijs NC, et al. Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity. Leukemia. 2005;19:1270-1272.
49. Sallusto F, Schaerli P, Loetscher P, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol. 1998;28:2760-2769.
50. Proudfoot O, Pouniotis D, Sheng KC, et al. Dendritic cell vaccination. Expert Rev Vaccines. 2007;6:617-633.
51. Houtenbos I, Westers TM, Ossenkoppele GJ, et al. Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization. Immunobiology. 2005;210:249-257.
52. Houtenbos I, Westers TM, Ossenkoppele GJ, et al. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. Haematologica. 2006;91: 348-355.
53. Houtenbos I, Westers TM, Ossenkoppele GJ, et al. Leukaemic dendritic cell vaccination for patients with acute myeloid leukaemia. Br J Haematol. 2006;134:445-446. (Pubitemid 44079559)